{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-001140","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.792236+00:00","generated_at":"2026-05-16T10:40:45.394968+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Moleculin reports no cardiotoxicity in 90 Annamycin subjects across five trials","bullets":["Independent expert review of 90 subjects across five clinical trials found no evidence of cardiotoxicity.","65 of 90 subjects received cumulative doses above FDA lifetime max of 550 mg/m2; one exceeded 6,500 mg/m2.","Data reviewed included serial ECGs, echocardiography with global longitudinal strain, and cardiac troponins.","Trials covered acute myeloid leukemia and soft tissue sarcoma, both as monotherapy and with cytarabine.","CEO cites potential for Annamycin to become first non-cardiotoxic anthracycline addressing high unmet need."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-001140","json":"https://secwatch.observer/filing/0001437749-26-001140.json","markdown":"https://secwatch.observer/filing/0001437749-26-001140.md","text":"https://secwatch.observer/filing/0001437749-26-001140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926001140/0001437749-26-001140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926001140/mbrx20260110c_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:40:45.394968+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}